Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
CYP19A1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AZALANSTAT | ↓ inhibits | Mechanistic | 7.6 nM (Ki) | DGIdb |
| NARINGENIN | ? unclear | Mechanistic | DGIdb | |
| TESTOLACTONE | ↓ inhibits | Mechanistic | 35000.0 nM (Ki) | DGIdb |
| ATROPINE | ? unclear | Mechanistic | DGIdb | |
| FADROZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| EXEMESTANE | ↓ inhibits | Mechanistic | DGIdb | |
| AMINOGLUTETHIMIDE | ↓ inhibits | Mechanistic | 600.0 nM (Ki) | DGIdb |
| LIOTHYRONINE | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN, SODIUM SALT | ? unclear | Mechanistic | DGIdb | |
| LIAROZOLE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1077603 | ? unclear | Mechanistic | DGIdb | |
| AZTREONAM | ? unclear | Mechanistic | DGIdb | |
| GONADOTROPIN-RELEASING HORMONE ANALOG | ? unclear | Mechanistic | DGIdb | |
| ISOPROTERENOL | ? unclear | Mechanistic | DGIdb | |
| CAPTOPRIL | ? unclear | Mechanistic | DGIdb | |
| TAMOXIFEN | ? unclear | Mechanistic | DGIdb | |
| LETROZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| ANASTROZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| ATAMESTANE | ? unclear | Mechanistic | DGIdb | |
| FORMESTANE | ? unclear | Mechanistic | 410.0 nM (IC50) | DGIdb |
| PHYTOESTROGEN | ? unclear | Mechanistic | DGIdb | |
| FADROZOLE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PHENYTOIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| ANABOLIC STEROID | ? unclear | Mechanistic | DGIdb | |
| TESTOSTERONE ENANTHATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL572637 | ? unclear | Mechanistic | DGIdb | |
| ADENOVIRUS VECTOR | ? unclear | Mechanistic | DGIdb | |
| ISOPROPYL ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| BIOFLAVONOID | ? unclear | Mechanistic | DGIdb | |
| ALENDRONATE SODIUM | ? unclear | Mechanistic | DGIdb | |
| CAPECITABINE | ? unclear | Mechanistic | DGIdb | |
| GENISTEIN | ? unclear | Mechanistic | DGIdb | |
| NONSTEROIDAL ANTIINFLAMMATORY DRUG | ? unclear | Mechanistic | DGIdb | |
| ENVIRONMENTAL ESTROGEN | ? unclear | Mechanistic | DGIdb | |
| ANDROSTENEDIONE | ? unclear | Mechanistic | DGIdb | |
| OPIATE | ? unclear | Mechanistic | DGIdb | |
| FLUOROURACIL | ? unclear | Mechanistic | DGIdb | |
| NORENDOXIFEN | ↓ inhibits | Mechanistic | DGIdb | |
| ENDOXIFEN | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 187 agents ranked by evidence tier.
ESR1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ESTRONE | ↑ activates | Mechanistic | 480.0 nM (EC50) | DGIdb |
| EVEROLIMUS | ? unclear | Mechanistic | DGIdb | |
| ANASTROZOLE | ? unclear | Mechanistic | DGIdb | |
| SIVIFENE | ? unclear | Mechanistic | DGIdb | |
| ARZOXIFENE | ~ modulates | Mechanistic | DGIdb | |
| ENDOXIFEN | ↓ inhibits | Mechanistic | DGIdb | |
| OSPEMIFENE | ↓ inhibits | Mechanistic | DGIdb | |
| RALOXIFEN | ? unclear | Mechanistic | DGIdb | |
| FULVESTRANT | ↓ inhibits | Mechanistic | 6.0 nM (IC50) | DGIdb |
| INAVOLISIB | ? unclear | Mechanistic | DGIdb | |
| TESTOSTERONE PROPIONATE | ? unclear | Mechanistic | DGIdb | |
| PHENYLMERCURIC ACETATE | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL CYPIONATE | ↑ activates | Mechanistic | DGIdb | |
| ESTROGEN | ? unclear | Mechanistic | DGIdb | |
| METHOXSALEN | ? unclear | Mechanistic | DGIdb | |
| BORIC ACID | ? unclear | Mechanistic | DGIdb | |
| IMLUNESTRANT | ↓ inhibits | Mechanistic | DGIdb | |
| PROTOAPIGENONE | ? unclear | Mechanistic | DGIdb | |
| CLOMIPHENE CITRATE | ? unclear | Mechanistic | DGIdb | |
| DAUNORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| NERATINIB | ? unclear | Mechanistic | DGIdb | |
| ALACHLOR | ? unclear | Mechanistic | DGIdb | |
| METHAMPHETAMINE | ? unclear | Mechanistic | DGIdb | |
| OCHRATOXIN A | ? unclear | Mechanistic | DGIdb | |
| CETRIMONIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| EXEMESTANE | ? unclear | Mechanistic | DGIdb | |
| GW7647 | ? unclear | Mechanistic | DGIdb | |
| NORGESTREL | ? unclear | Mechanistic | DGIdb | |
| AMCENESTRANT | ↓ inhibits | Mechanistic | DGIdb | |
| LETROZOLE | ? unclear | Mechanistic | DGIdb | |
| PROGESTERONE | ? unclear | Mechanistic | DGIdb | |
| DIETHYLSTILBESTROL | ↑ activates | Mechanistic | 12.0 nM (EC50) | DGIdb |
| ESTRIOL | ↑ activates | Mechanistic | DGIdb | |
| 16Α-HYDROXYESTRONE | ↑ activates | Mechanistic | DGIdb | |
| BRILANESTRANT | ? unclear | Mechanistic | DGIdb | |
| LEVONORGESTREL | ? unclear | Mechanistic | DGIdb | |
| ACOLBIFENE | ? unclear | Mechanistic | DGIdb | |
| PROPYLPYRAZOLETRIOL | ↑ activates | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ↑ activates | Mechanistic | DGIdb | |
| MEGESTROL | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 386 agents ranked by evidence tier.
ESR2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| OSPEMIFENE | ↓ inhibits | Mechanistic | DGIdb | |
| ESTRONE | ↑ activates | Mechanistic | 1135.0 nM (EC50) | DGIdb |
| LAPATINIB | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ↑ activates | Mechanistic | DGIdb | |
| FULVESTRANT | ↓ inhibits | Mechanistic | 7.0 nM (IC50) | DGIdb |
| DIETHYLSTILBESTROL | ↑ activates | Mechanistic | 9.0 nM (EC50) | DGIdb |
| RIBOCICLIB | ? unclear | Mechanistic | DGIdb | |
| PERTUZUMAB | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1222035 | ? unclear | Mechanistic | DGIdb | |
| ALENDRONATE SODIUM | ? unclear | Mechanistic | DGIdb | |
| LASOFOXIFENE TARTRATE | ~ modulates | Mechanistic | DGIdb | |
| LASOFOXIFENE | ↑ activates | Mechanistic | DGIdb | |
| TAMOXIFEN | ↓ inhibits | Mechanistic | DGIdb | |
| BAZEDOXIFENE ACETATE | ~ modulates | Mechanistic | DGIdb | |
| RALOXIFEN | ? unclear | Mechanistic | DGIdb | |
| FERB 033 | ↑ activates | Mechanistic | DGIdb | |
| ERTEBEREL | ? unclear | Mechanistic | DGIdb | |
| ABEMACICLIB | ? unclear | Mechanistic | DGIdb | |
| ESTRIOL | ↑ activates | Mechanistic | DGIdb | |
| GEMCITABINE | ? unclear | Mechanistic | DGIdb | |
| ALLYLESTRENOL | ↑ activates | Mechanistic | DGIdb | |
| R,R-THC | ↓ inhibits | Mechanistic | DGIdb | |
| IXABEPILONE | ? unclear | Mechanistic | DGIdb | |
| 4-HYDROXYTAMOXIFEN | ↓ inhibits | Mechanistic | DGIdb | |
| NORENDOXIFEN | ↑ activates | Mechanistic | DGIdb | |
| PRINABEREL | ↑ activates | Mechanistic | DGIdb | |
| WAY200070 | ↑ activates | Mechanistic | DGIdb | |
| (S)-LIQUIRITIGENIN | ↑ activates | Mechanistic | DGIdb | |
| EVEROLIMUS | ? unclear | Mechanistic | DGIdb | |
| GOSERELIN | ? unclear | Mechanistic | DGIdb | |
| TRASTUZUMAB | ? unclear | Mechanistic | DGIdb | |
| OLAPARIB | ? unclear | Mechanistic | DGIdb | |
| MF101 | ↑ activates | Mechanistic | DGIdb | |
| ESTETROL | ↑ activates | Mechanistic | DGIdb | |
| FAM-TRASTUZUMAB DERUXTECAN-NXKI | ? unclear | Mechanistic | DGIdb | |
| CHLOROTRIANISENE | ~ modulates | Mechanistic | DGIdb | |
| NARINGENIN | ? unclear | Mechanistic | DGIdb | |
| CAPIVASERTIB | ? unclear | Mechanistic | DGIdb | |
| INAVOLISIB | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ~ modulates | Mechanistic | 43.0 nM (IC50) | DGIdb |
Showing top 40 of 243 agents ranked by evidence tier.
GNRHR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LEUPROLIDE MESYLATE | ↑ activates | Mechanistic | DGIdb | |
| [TRP8]GNRH | ↑ activates | Mechanistic | DGIdb | |
| ZOPTARELIN DOXORUBICIN | ? unclear | Mechanistic | DGIdb | |
| LEUPROLIDE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| GONADORELIN | ? unclear | Mechanistic | DGIdb | |
| NBI-42902 | ↓ inhibits | Mechanistic | DGIdb | |
| T-98475 | ↓ inhibits | Mechanistic | DGIdb | |
| GANIRELIX ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| 5-(N,N-HEXAMETHYLENE)-AMILORIDE | ~ modulates | Mechanistic | DGIdb | |
| HISTRELIN | ↑ activates | Mechanistic | DGIdb | |
| GONADORELIN ACETATE | ↑ activates | Mechanistic | DGIdb | |
| RELUGOLIX | ↓ inhibits | Mechanistic | DGIdb | |
| LINZAGOLIX | ↓ inhibits | Mechanistic | DGIdb | |
| ELAGOLIX | ↓ inhibits | Mechanistic | DGIdb | |
| WAY-207024 | ↓ inhibits | Mechanistic | DGIdb | |
| [TYR8]GNRH | ↑ activates | Mechanistic | DGIdb | |
| GONADORELIN HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| D-23487 | ↓ inhibits | Mechanistic | DGIdb | |
| NAFARELIN | ↑ activates | Mechanistic | DGIdb | |
| OPIGOLIX | ↓ inhibits | Mechanistic | DGIdb | |
| DANAZOL | ? unclear | Mechanistic | DGIdb | |
| [SER8]GNRH | ↑ activates | Mechanistic | DGIdb | |
| GNRH I | ↑ activates | Mechanistic | DGIdb | |
| FD-1 | ↓ inhibits | Mechanistic | DGIdb | |
| SUFUGOLIX | ↓ inhibits | Mechanistic | DGIdb | |
| DESLORELIN ACETATE | ↑ activates | Mechanistic | DGIdb | |
| GNRH II | ↑ activates | Mechanistic | DGIdb | |
| HISTERELIN | ↑ activates | Mechanistic | DGIdb | |
| TRIPTORELIN PAMOATE | ? unclear | Mechanistic | DGIdb | |
| [125I][TYR5,DALA6,NMELEU7,PRO9-NET]GNRH | ↑ activates | Mechanistic | DGIdb | |
| HISTRELIN ACETATE | ↑ activates | Mechanistic | DGIdb | |
| UCALOLICTIDE | ? unclear | Mechanistic | DGIdb | |
| DEGARELIX ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| ALARELIN | ↑ activates | Mechanistic | DGIdb | |
| GOSERELIN | ↑ activates | Mechanistic | DGIdb | |
| FERTIRELIN | ↑ activates | Mechanistic | DGIdb | |
| ACYLINE | ? unclear | Mechanistic | DGIdb | |
| GNRH III | ↑ activates | Mechanistic | DGIdb | |
| ITURELIX | ↓ inhibits | Mechanistic | DGIdb | |
| NAFARELIN ACETATE | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 221 agents ranked by evidence tier.
HSD17B1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL1627453 | ↓ inhibits | Mechanistic | 420.0 nM (IC50) | ChEMBL |
| CHEMBL1627450 | ↓ inhibits | Mechanistic | 460.0 nM (IC50) | ChEMBL |
| CHEMBL1627455 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL1627884 | ↓ inhibits | Mechanistic | 4300.0 nM (IC50) | ChEMBL |
| CHEMBL1627451 | ↓ inhibits | Mechanistic | 1150.0 nM (IC50) | ChEMBL |
| CHEMBL307621 | ↓ inhibits | Mechanistic | 59000.0 nM (Ki) | ChEMBL |
| CHEMBL75893 | ↓ inhibits | Mechanistic | 65000.0 nM (Ki) | ChEMBL |
| CHEMBL76061 | ↓ inhibits | Mechanistic | 2800.0 nM (Ki) | ChEMBL |
| CHEMBL1627749 | ↓ inhibits | Mechanistic | 37.0 nM (IC50) | ChEMBL |
| CHEMBL1627752 | ↓ inhibits | Mechanistic | 27.0 nM (IC50) | ChEMBL |
| CHEMBL1627742 | ↓ inhibits | Mechanistic | 290.0 nM (IC50) | ChEMBL |
| CHEMBL1627759 | ↓ inhibits | Mechanistic | 10000.0 nM (IC50) | ChEMBL |
| CHEMBL369897 | ↓ inhibits | Mechanistic | 110.0 nM (IC50) | ChEMBL |
| CHEMBL1627756 | ↓ inhibits | Mechanistic | 1100.0 nM (IC50) | ChEMBL |
| CHEMBL198223 | ↓ inhibits | Mechanistic | 180.0 nM (IC50) | ChEMBL |
| CHEMBL198613 | ↓ inhibits | Mechanistic | 2750.0 nM (IC50) | ChEMBL |
| CHEMBL365752 | ↓ inhibits | Mechanistic | 920.0 nM (IC50) | ChEMBL |
| CHEMBL194579 | ↓ inhibits | Mechanistic | 530.0 nM (IC50) | ChEMBL |
| CHEMBL197056 | ↓ inhibits | Mechanistic | 730.0 nM (IC50) | ChEMBL |
| CHEMBL372540 | ↓ inhibits | Mechanistic | 1850.0 nM (IC50) | ChEMBL |
| CHEMBL381466 | ↓ inhibits | Mechanistic | 950.0 nM (IC50) | ChEMBL |
| CHEMBL434950 | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| CHEMBL364060 | ↓ inhibits | Mechanistic | 780.0 nM (IC50) | ChEMBL |
| CHEMBL438624 | ↓ inhibits | Mechanistic | 880.0 nM (IC50) | ChEMBL |
| CHEMBL194690 | ↓ inhibits | Mechanistic | 300.0 nM (IC50) | ChEMBL |
| CHEMBL370570 | ↓ inhibits | Mechanistic | 13500.0 nM (IC50) | ChEMBL |
| CHEMBL370571 | ↓ inhibits | Mechanistic | 6900.0 nM (IC50) | ChEMBL |
| CHEMBL382114 | ↓ inhibits | Mechanistic | 90.0 nM (IC50) | ChEMBL |
| CHEMBL331544 | ↓ inhibits | Mechanistic | 310.0 nM (IC50) | ChEMBL |
| CHEMBL170583 | ↓ inhibits | Mechanistic | 120.0 nM (IC50) | ChEMBL |
| CHEMBL369588 | ↓ inhibits | Mechanistic | 430.0 nM (IC50) | ChEMBL |
| CHEMBL332756 | ↓ inhibits | Mechanistic | 93.0 nM (IC50) | ChEMBL |
| CHEMBL371948 | ↓ inhibits | Mechanistic | 52.0 nM (IC50) | ChEMBL |
| CHEMBL372560 | ↓ inhibits | Mechanistic | 140.0 nM (IC50) | ChEMBL |
| CHEMBL198558 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL1628005 | ↓ inhibits | Mechanistic | 340.0 nM (IC50) | ChEMBL |
| CHEMBL1627790 | ↓ inhibits | Mechanistic | 320.0 nM (IC50) | ChEMBL |
| ESTRONE | ↓ inhibits | Mechanistic | 330.0 nM (IC50) | ChEMBL |
| CHEMBL1628135 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL1628021 | ↓ inhibits | Mechanistic | 380.0 nM (IC50) | ChEMBL |
Showing top 40 of 169 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA EXTRACT | ? unclear | Mechanistic | DGIdb | |
| NELFINAVIR | ? unclear | Mechanistic | DGIdb | |
| SELECTIVE ESTROGEN RECEPTOR MODULATOR | ? unclear | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| SITAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| PACIBEKITUG | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| SAFINGOL | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| RITUXIMAB | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| C326 | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| OSIMERTINIB | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| ALOGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| TENELIGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| TOCILIZUMAB | ? unclear | Mechanistic | DGIdb | |
| LINAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| VILDAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| PAREGORIC | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 181 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FASINUMAB | ? unclear | Mechanistic | DGIdb | |
| CERE-110 | ? unclear | Mechanistic | DGIdb | |
| TANEZUMAB | ? unclear | Mechanistic | DGIdb | |
| FRUNEVETMAB | ~ modulates | Mechanistic | DGIdb | |
| FULRANUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PG-110 | ↓ inhibits | Mechanistic | DGIdb | |
| BEDINVETMAB | ~ modulates | Mechanistic | DGIdb | |
| MEDI-578 | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL1397270 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ETHYNODIOL DIACETATE | ↑ activates | Mechanistic | DGIdb | |
| MIFEPRISTONE | ↓ inhibits | Mechanistic | 0.028 nM (IC50) | DGIdb |
| LAPATINIB | ? unclear | Mechanistic | DGIdb | |
| ETONOGESTREL | ↑ activates | Mechanistic | DGIdb | |
| GESTODENE | ↑ activates | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| PROGESTERONE | ↑ activates | Mechanistic | 2.9 nM (EC50) | DGIdb |
| NERATINIB | ? unclear | Mechanistic | DGIdb | |
| NORELGESTROMIN | ↑ activates | Mechanistic | DGIdb | |
| ZK112993 | ↓ inhibits | Mechanistic | DGIdb | |
| ASOPRISNIL | ↓ inhibits | Mechanistic | DGIdb | |
| NORGESTIMATE | ↑ activates | Mechanistic | DGIdb | |
| TELAPRISTONE | ? unclear | Mechanistic | DGIdb | |
| CYPROTERONE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| CHLORMADINONE ACETATE | ~ modulates | Mechanistic | DGIdb | |
| TAMOXIFEN | ? unclear | Mechanistic | DGIdb | |
| EXEMESTANE | ? unclear | Mechanistic | DGIdb | |
| PERTUZUMAB | ? unclear | Mechanistic | DGIdb | |
| PROGESTIN | ? unclear | Mechanistic | DGIdb | |
| MEGESTROL ACETATE | ↑ activates | Mechanistic | DGIdb | |
| PROGESTOGEN | ? unclear | Mechanistic | DGIdb | |
| LONAPRISAN | ↓ inhibits | Mechanistic | DGIdb | |
| NORGESTREL | ↑ activates | Mechanistic | DGIdb | |
| NOMEGESTROL | ↑ activates | Mechanistic | DGIdb | |
| MEDROXYPROGESTERONE ACETATE | ↑ activates | Mechanistic | 0.15 nM (EC50) | DGIdb |
| ULIPRISTAL | ~ modulates | Mechanistic | DGIdb | |
| DYDROGESTERONE | ↑ activates | Mechanistic | DGIdb | |
| NORETHYNODREL | ↑ activates | Mechanistic | DGIdb | |
| ERIBULIN | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE/DIENOGEST | ? unclear | Mechanistic | DGIdb | |
| NORETHINDRONE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| PROMEGESTONE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2059711 | ? unclear | Mechanistic | DGIdb | |
| LETROZOLE | ? unclear | Mechanistic | DGIdb | |
| DANAZOL | ↑ activates | Mechanistic | DGIdb | |
| ULIPRISTAL ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| APR19 | ↓ inhibits | Mechanistic | DGIdb | |
| PALBOCICLIB | ? unclear | Mechanistic | DGIdb | |
| PF-05019702 | ↓ inhibits | Mechanistic | DGIdb | |
| VILAPRISAN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 158 agents ranked by evidence tier.
PTGS2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CURCUMIN PYRAZOLE | ? unclear | Mechanistic | DGIdb | |
| CAPECITABINE | ? unclear | Mechanistic | DGIdb | |
| DIFLUNISAL | ↓ inhibits | Mechanistic | DGIdb | |
| ROFECOXIB | ↓ inhibits | Mechanistic | 530.0 nM (IC50) | DGIdb |
| KETOROLAC TROMETHAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| DEXIBUPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| BALSALAZIDE | ? unclear | Mechanistic | DGIdb | |
| ESFLURBIPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| NAPROXEN ETEMESIL | ? unclear | Mechanistic | DGIdb | |
| SUPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| PEPTIDE 30 [PMID: 27019010] | ↓ inhibits | Mechanistic | DGIdb | |
| NEPAFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| APRICOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| APAZONE | ↓ inhibits | Mechanistic | DGIdb | |
| SALICYLIC ACID | ? unclear | Mechanistic | DGIdb | |
| TIAPROFENIC ACID | ? unclear | Mechanistic | DGIdb | |
| KETOPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| RESERPINE | ? unclear | Mechanistic | DGIdb | |
| NS-398 | ↓ inhibits | Mechanistic | DGIdb | |
| NABUMETONE | ↓ inhibits | Mechanistic | DGIdb | |
| SULINDAC | ↓ inhibits | Mechanistic | DGIdb | |
| ETODOLAC | ↓ inhibits | Mechanistic | DGIdb | |
| MEFENAMIC ACID | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ETORICOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| VALDECOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| IBUFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| DEXKETOPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| GLAFENINE | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 9 [KUMAR ET AL., 2019] | ↓ inhibits | Mechanistic | DGIdb | |
| RESVERATROL | ↓ inhibits | Mechanistic | DGIdb | |
| SWE101 | ↓ inhibits | Mechanistic | DGIdb | |
| INDOMETHACIN | ↓ inhibits | Mechanistic | 5.9 nM (IC50) | DGIdb |
| NAPROXCINOD | ↓ inhibits | Mechanistic | DGIdb | |
| HR1405-01 | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC ETALHYALURONATE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 12A [PMID: 29031075] | ↓ inhibits | Mechanistic | DGIdb | |
| TOLMETIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| OXYPHENBUTAZONE | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC POTASSIUM | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 309 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DICLOFENAC SODIUM | ? unclear | Mechanistic | DGIdb | |
| RDP58 | ? unclear | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ORTATAXEL | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| HUANG LIAN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| HALOFUGINONE | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ISIS 104838 | ? unclear | Mechanistic | DGIdb | |
| GEMCITABINE | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| DIDANOSINE | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SOBLIDOTIN | ? unclear | Mechanistic | DGIdb | |
| STAVUDINE | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| MEROPENEM ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| AMPHOTERICIN B LIPOSOMAL | ? unclear | Mechanistic | DGIdb | |
| MIDAZOLAM HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RIFAMPIN | ? unclear | Mechanistic | DGIdb | |
| AVX-470 | ? unclear | Mechanistic | DGIdb | |
| KETOROLAC TROMETHAMINE | ? unclear | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| ETHAMBUTOL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SPIRONOLACTONE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| MITOMYCIN C ANALOG KW-2149 | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| ABBV-3373 | ~ modulates | Mechanistic | DGIdb | |
| BACILLUS CALMETTE-GUERIN ANTIGEN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 287 agents ranked by evidence tier.
VEGFA
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| BEVASIRANIB | ? unclear | Mechanistic | DGIdb | |
| RANIBIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CP-547632 | ? unclear | Mechanistic | DGIdb | |
| EW-A-401 | ? unclear | Mechanistic | DGIdb | |
| BEVACIZUMAB 111IN | ~ modulates | Mechanistic | DGIdb | |
| FENOFIBRATE MICRONIZED | ? unclear | Mechanistic | DGIdb | |
| PEGAPTANIB | ↓ inhibits | Mechanistic | DGIdb | |
| DEXAMETHASONE | ? unclear | Mechanistic | DGIdb | |
| SQUALAMINE | ? unclear | Mechanistic | DGIdb | |
| AFLIBERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| PAZOPANIB | ? unclear | Mechanistic | DGIdb | |
| BEVACIZUMAB GAMMA | ~ modulates | Mechanistic | DGIdb | |
| CILOSTAZOL | ? unclear | Mechanistic | DGIdb | |
| ADALIMUMAB | ? unclear | Mechanistic | DGIdb | |
| MUPARFOSTAT | ↓ inhibits | Mechanistic | DGIdb | |
| SILDENAFIL | ? unclear | Mechanistic | DGIdb | |
| PENTOSAN POLYSULFATE | ? unclear | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| RISUTEGANIB | ? unclear | Mechanistic | DGIdb | |
| SELECTIVE CYTOKINE INHIBITORY DRUG CC-1088 | ? unclear | Mechanistic | DGIdb | |
| PHENETHYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| EMVODODSTAT | ? unclear | Mechanistic | DGIdb | |
| CARFILZOMIB | ? unclear | Mechanistic | DGIdb | |
| FARICIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ALBUTEROL SULFATE | ? unclear | Mechanistic | DGIdb | |
| LENALIDOMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SUNITINIB | ? unclear | Mechanistic | DGIdb | |
| SHARK CARTILAGE EXTRACT AE-941 | ? unclear | Mechanistic | DGIdb | |
| NM-3 | ? unclear | Mechanistic | DGIdb | |
| DILPACIMAB | ? unclear | Mechanistic | DGIdb | |
| PEMETREXED DISODIUM | ? unclear | Mechanistic | DGIdb | |
| BI-836880 | ? unclear | Mechanistic | DGIdb | |
| BROLUCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| DOMATINOSTAT | ? unclear | Mechanistic | DGIdb | |
| ANTHRACYCLINE ANTINEOPLASTIC ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| VEGF/HGF-TARGETING DARPIN MP0250 | ? unclear | Mechanistic | DGIdb | |
| WARFARIN | ? unclear | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| NAVICIXIZUMAB | ? unclear | Mechanistic | DGIdb | |
| VEGLIN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 207 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Endometriosis: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
The goal of this clinical trial is to find out how the study drug HHK001 compares to Enantone (an approved treatment for endometriosis) when given as a single 3.75 mg injection to participants with endometriosis. Both products contain the same active ingredient: leuprorelin acetate. We will check ho...
This study aims to evaluate the effects of therapy with implantable Gestrinone compared to oral Dienogest in relieving complaints related to endometriosis.
The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectru...
This prospective study targets infertile women with endometriosis (EM) who have experienced a previously failed Intracytoplasmic Sperm Injection (ICSI) trial. Using the P-I-C-O framework, the study evaluates whether the administration of an anti-TNF-α therapy (Intervention) 4-5 days before a frozen ...
A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension
Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy fo...
Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endomet...
The goal of this investigator-initiated single-site clinical trial is to compare the overall quality of life of participants taking Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis to participants that do not take Rel-CT following the same surgery. Rel-CT is an F...
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives ...
Pelvic pain is considered a symptom of multifactorial origin among which Endometriosis is the main gynecological cause affecting 5-10% of worldwide women in their reproductive years, negatively impacting their quality of life and work efficiency. Treatment of endometriosis-associated pelvic pain is ...
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Agents Found By Disease-Level Search
Searched directly from “Endometriosis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
42 agents shown (approved or with trial evidence) — 40 not found by the gene-target search above.
Elagolix
GnRH-analogueNOT in gene-target list
Letrozole
BAY1817080 - Formulation ANOT in gene-target list
BAY1817080 - Formulation BNOT in gene-target list
Closure of the Vaginal Cuff after Total HysterectomyNOT in gene-target list
Alcohol sclerotherapyNOT in gene-target list
Circulating DNA analysisNOT in gene-target list
Vaginal microbiota analysisNOT in gene-target list
Endometrial microbiota analysisNOT in gene-target list
Intestinal microbiota analysisNOT in gene-target list
Exposure to endocrine disruptors analysisNOT in gene-target list
Specialized kitNOT in gene-target list
conventional laparoscopic hysterectomyNOT in gene-target list
robotic assisted laparoscopic hysterectomyNOT in gene-target list
Human Chorionic Gonadotropin (hCG)NOT in gene-target list
GonadotropinsNOT in gene-target list
GNRH-A TriptorelinNOT in gene-target list
GnRH antagonistNOT in gene-target list
Laparoscopic cystectomyNOT in gene-target list
Rectal water-contrast transvaginal ultrasonographyNOT in gene-target list
SonovaginographyNOT in gene-target list
BAY2328065 LSFNOT in gene-target list
BAY2328065 tabletNOT in gene-target list
MidazolamNOT in gene-target list
ENDO 1/ENDO 2NOT in gene-target list
Tab.Dienogest 2 mgNOT in gene-target list
Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tabletNOT in gene-target list
Melatonin 10 mgNOT in gene-target list
Melatonin 20 mgNOT in gene-target list
Rectal/colorectal segmental resectionNOT in gene-target list
Rectal nodule excisionNOT in gene-target list
Food supplement (T1675)NOT in gene-target list
DiathermyNOT in gene-target list
Argon Beam CoagulatorNOT in gene-target list
Ziwig Endotest®NOT in gene-target list
Intrauterine inseminationNOT in gene-target list
linzagolix (OBE2109)NOT in gene-target list
Expectant managementNOT in gene-target list
Three-dimensional (3D) rectal water contrast transvaginal ultrasonographyNOT in gene-target list
Computed colonographyNOT in gene-target list
A non-invasive blood-based (HerResolve)NOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.